Osimertinib Recruiting Phase 2 Trials for EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs